China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large and the only healthcare-centered group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council. With a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, medical care and health, engineering services, exhibitions and conferences, international business and financial services, Sinopharm takes a leading position in China and Asia at large in term of composite power and scale. Sinopharm owns over 1,600 subsidiaries with 210,000 employees and 8 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., China Traditional Chinese Medicine Holdings Co., Ltd., Sinopharm Taiji Group and Beijing Strong Biotechnologies, Inc.

In 2021, the operation revenue of Sinopharm exceeded 700 billion Chinese yuan, ranking it at 80^th on the Fortune Global 500 and 1^nd among the healthcare enterprise on the list. With its scale, achievements and composite power continuously leading in China and Asia's healthcare sector, besides the multiple national awards, Sinopharm successively ranked No.1 among all Asian enterprises on the Brand Finance's Pharma 25 2021 list.

Looking into the future, Sinopharm will continue to adhere to aspiration and commission of “all for health, health for all” and tap into its well-established platform in the industry to serve the national Healthy China initiative. And by vigorously implementing the overall strategic plan of a new innovation-driven life cycle and ecosystem covering a whole industrial chain, Sinopharm will keep its effort in building into a world-class comprehensive healthcare group with global competitiveness.